Recombinant Cynomolgus / Rhesus macaque TIGIT Protein, Mouse IgG2a Fc Tag (MALS verified), 50 µg

Background
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is also known as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane domain-containing protein 3 (VSTM3),which belongs to single-pass type I membrane protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level). TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.

Source
Recombinant Cynomolgus / Rhesus macaque TIGIT, Mouse IgG2a Fc Tag (TIT-C5253) is expressed from human 293 cells (HEK293). It contains AA Met 89 - Ile 208 (Accession # G7NXM4-1).
Predicted N-terminus: Met 89

Molecular Characterization
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 40.2 kDa. The protein migrates as 45-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation

Endotoxin
Less than 0.1 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells"
Piovesan, de Groot, Cho et al
Cancer Res (2024)
(2) "A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma"
Assal, Elemam, Mekky et al
Transl Oncol (2024) 45, 101961
(3) "Structural basis for the immune recognition and selectivity of the immune receptor PVRIG for ligand Nectin-2"
Hu, Han, Wang et al
Structure (2024)
Showing 1-3 of 1505 papers.